个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共13条记录   Editorial: Endocannabinoid signaling and neuroinflammatory diseases [作者：Maccarrone, M,期刊：Current Pharmaceutical Design, 页码：2252-2253 , 文章类型： Editorial Material，,卷期：2008年14-23] The endocannabinoid system in Huntington's disease [作者：Pazos, MR; Sagredo, O; Fernandez-Ruiz, J,期刊：Current Pharmaceutical Design, 页码：2317-2325 , 文章类型： Review，,卷期：2008年14-23] The hypokinetic profile of certain cannabinoid agonists becomes these compounds as promising medicines to attenuate the hyperkinesia that characterizes the first grades of Huntington's disease (HD) and that represents th... Role of cannabinoids and endocannabinoids in cerebral ischemia [作者：Hillard, CJ,期刊：Current Pharmaceutical Design, 页码：2347-2361 , 文章类型： Review，,卷期：2008年14-23] The human costs of stroke are very large and growing; it is the third largest cause of death in the United States and survivors are often faced with loss of ability to function independently. There is a large need for th... Endocannabinoids in liver disease and hepatic encephalopathy [作者：Magen, I; Avraham, Y; Berry, E; Mechoulam, R,期刊：Current Pharmaceutical Design, 页码：2362-2369 , 文章类型： Review，,卷期：2008年14-23] Chronic liver disease results from a variety of causes such as hepatitis virus infections, autoimmune processes and alcohol consumption. Its complications include fat deposition, hemodynamic changes and fibrosis. Clinica... The endocannabinoid system in peripheral lymphocytes as a mirror of neuroinflammatory diseases [作者：Centonze, D; Battistini, L; Maccarrone, M,期刊：Current Pharmaceutical Design, 页码：2370-2382 , 文章类型： Review，,卷期：2008年14-23] During immuno-mediated attack of the brain, activation of endocannabinoids represents a protective mechanism, aimed at reducing both neurodegenerative and inflammatory damage through various and partially converging mech... The tools of the trade - An overview of the pharmacology of the endocannabinoid system [作者：Fowler, CJ,期刊：Current Pharmaceutical Design, 页码：2254-2265 , 文章类型： Review，,卷期：2008年14-23] The endocannabinoid system can be manipulated pharmacologically in a variety of ways, including directly acting agonists and inverse agonists, and indirectly acting compounds which affect the synthesis, cellular accumula... CNS immune surveillance and neuroinflammation: Endocannabinoids keep control [作者：Wolf, SA; Tauber, S; Ullrich, O,期刊：Current Pharmaceutical Design, 页码：2266-2278 , 文章类型： Review，,卷期：2008年14-23] To avoid inflammatory escalation, the central nervous system (CNS) harbors an impressive arsenal of cellular and molecular mechanisms enabling strict control of immune reactions. We here summarize studies suggesting that... Mechanisms of control of neuron survival by the endocannabinoid system [作者：Galve-Roperh, I; Aguado, T; Palazuelos, J; Guzman, M,期刊：Current Pharmaceutical Design, 页码：2279-2288 , 文章类型： Review，,卷期：2008年14-23] Endocannabinoids act as retrograde messengers that, by inhibiting neurotransmitter release via presynaptic CB1 cannabinoid receptors, regulate the functionality of many synapses. In addition, the endocannabinoid system p... Expression and function of the endocannabinoid system in glial cells [作者：Massi, P; Valenti, M; Bolognini, D; Parolaro, D,期刊：Current Pharmaceutical Design, 页码：2289-2298 , 文章类型： Review，,卷期：2008年14-23] In the last few years the role and significance of the glia in CNS function and pathology have been drastically reassessed. Glial cells physiology appears very different in healthy versus pathological brain and the recen... The role of the endocannabinoid system in Alzheimer's disease: Facts and hypotheses [作者：Bisogno, T; Di Marzo, V,期刊：Current Pharmaceutical Design, 页码：2299-2305 , 文章类型： Review，,卷期：2008年14-23] Unlike other neuroinflammatory disorders, like Parkinson's disease, Huntington's disease and multiple sclerosis, little is still known of the role of the endocannabinoid system in Alzheimer's disease (AD). This is partly... The endocannabinoid system in amyotrophic lateral sclerosis [作者：Bilsland, LG; Greensmith, L,期刊：Current Pharmaceutical Design, 页码：2306-2316 , 文章类型： Review，,卷期：2008年14-23] Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative condition characterised by the selective loss of motor neurons from the spinal cord, brainstem and motor cortex. Although the pathogenic mechanisms that un... The endocannabinoid system and multiple sclerosis [作者：Baker, D; Pryce, G,期刊：Current Pharmaceutical Design, 页码：2326-2336 , 文章类型： Review，,卷期：2008年14-23] Multiple sclerosis (MS) is a neurodegenerative disease that is characterised by repeated inflammatory/demyelinating events within the central nervous system (CNS). In addition to relapsing-remitting neurological insults,... The endocannabinoid system in Parkinson's disease [作者：Di Filippo, M; Picconi, B; Tozzi, A; Ghiglieri, V; Rossi, A; Calabresi, P,期刊：Current Pharmaceutical Design, 页码：2337-2346 , 文章类型： Review，,卷期：2008年14-23] Parkinson's disease (PD) is a chronic and progressive neurodegenerative disorder of largely unknown etiology caused by a pathological cascade resulting in the degeneration of midbrain dopaminergic neurons of the substant...